Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) insider Francis Burrows sold 1,311 shares of the firm's stock in a transaction on Tuesday, January 27th. The stock was sold at an average price of $8.46, for a total transaction of $11,091.06. Following the transaction, the insider directly owned 32,424 shares of the company's stock, valued at approximately $274,307.04. This trade represents a 3.89% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Francis Burrows also recently made the following trade(s):
- On Thursday, December 18th, Francis Burrows sold 23,726 shares of Kura Oncology stock. The shares were sold at an average price of $9.78, for a total transaction of $232,040.28.
Kura Oncology Price Performance
Shares of KURA opened at $8.47 on Wednesday. The business's 50-day moving average is $10.33 and its two-hundred day moving average is $9.05. The company has a market capitalization of $737.06 million, a P/E ratio of -3.42 and a beta of 0.25. Kura Oncology, Inc. has a fifty-two week low of $5.41 and a fifty-two week high of $12.49. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.12 and a current ratio of 5.12.
Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its earnings results on Tuesday, November 4th. The company reported ($0.85) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.28). The company had revenue of $20.75 million during the quarter, compared to analysts' expectations of $17.48 million. Kura Oncology had a negative return on equity of 65.42% and a negative net margin of 208.48%. Research analysts predict that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its holdings in Kura Oncology by 2.2% in the 3rd quarter. Vanguard Group Inc. now owns 5,468,522 shares of the company's stock worth $48,396,000 after buying an additional 120,197 shares during the last quarter. EcoR1 Capital LLC lifted its position in shares of Kura Oncology by 59.1% in the second quarter. EcoR1 Capital LLC now owns 4,200,000 shares of the company's stock valued at $24,234,000 after acquiring an additional 1,559,702 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its stake in shares of Kura Oncology by 101.6% in the third quarter. Jacobs Levy Equity Management Inc. now owns 2,224,590 shares of the company's stock worth $19,688,000 after acquiring an additional 1,121,228 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Kura Oncology by 11.7% in the second quarter. Geode Capital Management LLC now owns 2,014,029 shares of the company's stock worth $11,623,000 after acquiring an additional 211,470 shares during the last quarter. Finally, Qube Research & Technologies Ltd increased its position in shares of Kura Oncology by 63.0% during the second quarter. Qube Research & Technologies Ltd now owns 1,911,886 shares of the company's stock worth $11,032,000 after purchasing an additional 738,761 shares in the last quarter.
Key Kura Oncology News
Here are the key news stories impacting Kura Oncology this week:
- Negative Sentiment: Teresa Brophy Bair (insider) sold 11,208 shares at an average price of $8.46 for proceeds of $94,819.68; her post-sale holdings are 226,931 shares (down ~4.71%). Read More.
- Negative Sentiment: Francis Burrows (insider) sold 1,311 shares at $8.46 for proceeds of $11,091.06; post-sale holdings 32,424 shares (down ~3.89%). Read More.
- Negative Sentiment: Thomas James Doyle (SVP) sold 7,142 shares at $8.46 for proceeds of $60,421.32; post-sale holdings 145,167 shares (down ~4.69%). Read More.
- Negative Sentiment: Mollie Leoni (insider) sold 8,180 shares at $8.46 for proceeds of $69,202.80; post-sale holdings 267,274 shares (down ~2.97%). Read More.
- Negative Sentiment: Kathleen Ford (COO) sold 1,813 shares at $8.46 for proceeds of $15,337.98; post-sale holdings 153,560 shares (down ~1.17%). Read More.
Analysts Set New Price Targets
Several equities analysts have recently weighed in on the stock. JMP Securities reaffirmed a "market outperform" rating and set a $24.00 target price on shares of Kura Oncology in a report on Monday, October 20th. Leerink Partners set a $20.00 price objective on shares of Kura Oncology and gave the company an "outperform" rating in a report on Tuesday, January 13th. Zacks Research lowered shares of Kura Oncology from a "hold" rating to a "strong sell" rating in a research note on Tuesday, January 20th. Weiss Ratings restated a "sell (d-)" rating on shares of Kura Oncology in a research note on Thursday, January 22nd. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $40.00 price target on shares of Kura Oncology in a report on Tuesday, January 13th. Nine investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $28.00.
Get Our Latest Stock Analysis on KURA
About Kura Oncology
(
Get Free Report)
Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura's research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.
The company's lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
